On Monday, Agilent Technologies announced its acquisition of privately-held life sciences software developer Silicon Genetics. By adding Silicon Genetics genomics data analysis and management tools, Agilent is hoping to gain a foothold in life sciences informatics.
In the most recent fiscal year, Agilent derived 42 percent of its revenue from test and measurement tools, 13 percent from automated testing tools, 26 percent from semiconductor products, and 20 percent from chemical analysis. For that year, revenue was virtually stagnant at $6.1 billion.
Financial terms of the Silicon Genetics deal remain disclosed.
Read the full story at Bio-IT World
